LongevityNext
Argue that consolidation may happen first in care delivery and diagnostics infrastructure rather than pure therapeutics. The piece keeps the focus on evidence, commercial logic, and what would…
Menopause, ovarian aging, cardiometabolic risk, bone, brain, and care-delivery models create a bridge between longevity and women's health. The piece keeps the focus on evidence, commercial logic, and…
Use the NewLimit $435 million financing as a market signal: investors are buying a long-duration option on controllable reprogramming, not a simple proof that rejuvenation medicine is ready.…
Recent longevity deals are not funding one grand anti-aging thesis. They are clustering around businesses that make longevity legible as diagnostics, animal-health therapeutics, and platform discovery.
There is a temptation to talk about longevity investing as if it were a single sector. It is not. The label now covers everything from blood-test memberships and…